Abstract
Global prevalence and increasing incidence rates of type 2 diabetes (T2D) has rippling effects on healthcare costs and diminishing quality of life. Despite advances in technology, continuous subcutaneous insulin infusions (CSII), or insulin pump therapy, is rarely being recommended by health care professionals (HCP) and is underutilized in T2D management. This review analyzes the available literature for CSII use in T2D patients. Moreover, it discusses which groups of patients may benefit from CSII, potential challenges to CSII use, and suggests future directions for research to expand the applicability of this technology to the broader T2D population. This article is protected by copyright. All rights reserved.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
